ArticleJournal of racial and ethnic health disparities2026
Analgesic Utilization Pattern and Cost of Managing Children with Sickle Cell Diseases: a Retrospective Single-site Audit.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background informationSickle cell disease (SCD), a β-haemoglobinopathy, is a neglected multi-system disorder caused by inherited abnormal haemoglobin structure or production and leads to catastrophic economic burden on affected households and societies. We assessed the predictors of both SCD severity and SCD care costs.
methodsThis is a retrospective chart review of eligible children with SCD in a developing setting. Their sociodemographic, clinical and costs data were collected and analyzed using SPSS version 26.0 with p ≤ 0.05 considered significant.
resultsOverall 2503 children with SCD (female: 1053 [51.3%]; median (interquartile range) age: 4.00 (5.75) years and range age: 0.08-14.00 years) participated in the study with their median (interquartile range) age at first pain crisis, age at first hospitalization, costs of outpatient, inpatient and total patient care; analgesics and laboratory investigations being 1.00 (1.25) years, 1.00 (1.13) years, 89.8 (110.6) USD, 47.9 (63.4) USD and 200.4 (158.8) USD; 3.8 (3.5) USD and 28.6 (16.9) USD respectively. The major predictors of SCD severity were [hospitalization frequency: use of parenteral non-opioids (odds ratio (OR): 8.65; 95% CI:3.84-19.46; p < 0.001) and having a history of parental consanguinity (OR: 6.28; 95% CI:1.59-24.86; p = 0.009); hospitalization duration: having a history of parental consanguinity (OR: 3.73; 95% CI:2.03-6.83; p < 0.001) and type of oral analgesics (OR: 3.28; 95% CI:2.57-4.17; p < 0.001)]. The major predictors of the following cost variables were: analgesics [total amount of non-opioids (OR: 2.34; 95% CI:2.10-2.60; p < 0.001) and total number of oral opioids (OR: 4.56; 95% CI:3.60-5.78; p < 0.001)]; laboratory investigation [total amount of oral opioids (OR: 1.41; 95% CI:1.27-1.56; p = 0.0005)]; outpatient care [school attendance (OR: 20.64; 95% CI:10.47-40.69; p < 0.001), comorbidity (OR: 2.68; 95% CI:1.52-4.75; p < 0.001) and pentazocine (OR: 1.32; 95% CI:1.12-1.56; p < 0.001)]; inpatient care [having a history of parental consanguinity (OR: 10.67; 95% CI:4.81-23.67; p < 0.001)] and total patient care [pentazocine (OR: 14.75; 95% CI:10.17-35.68; p < 0.001)].
conclusionConsanguinity and analgesics use were the major predictors of both SCD severity and SCD care costs.
Indexed as
Identifiers
42032171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.